Axsome Therapeutics (AXSM) Expected to Announce Quarterly Earnings on Monday

Axsome Therapeutics (NASDAQ:AXSM) is projected to post its Q4 2025 results before the market opens on Monday, February 23rd. Analysts expect Axsome Therapeutics to post earnings of ($0.72) per share and revenue of $191.3340 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, February 23, 2026 at 8:00 AM ET.

Axsome Therapeutics Trading Down 0.9%

Shares of NASDAQ AXSM opened at $181.21 on Monday. The business’s 50 day moving average is $170.27 and its two-hundred day moving average is $141.61. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.50. Axsome Therapeutics has a 1-year low of $86.99 and a 1-year high of $191.50. The stock has a market capitalization of $9.13 billion, a P/E ratio of -38.80, a PEG ratio of 11.70 and a beta of 0.40.

Insiders Place Their Bets

In other news, Director Mark E. Saad sold 37,577 shares of the company’s stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $165.18, for a total value of $6,206,968.86. Following the transaction, the director directly owned 10,002 shares in the company, valued at approximately $1,652,130.36. This represents a 78.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Herriot Tabuteau sold 32,410 shares of the business’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $185.60, for a total transaction of $6,015,296.00. Following the completion of the sale, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at approximately $1,341,702.40. This trade represents a 81.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 308,874 shares of company stock valued at $51,390,805 in the last three months. 22.40% of the stock is owned by company insiders.

Institutional Trading of Axsome Therapeutics

Large investors have recently modified their holdings of the company. Birchview Capital LP raised its position in Axsome Therapeutics by 1.0% during the 4th quarter. Birchview Capital LP now owns 6,061 shares of the company’s stock valued at $1,107,000 after purchasing an additional 61 shares in the last quarter. Xponance LLC grew its position in shares of Axsome Therapeutics by 2.4% during the 4th quarter. Xponance LLC now owns 3,265 shares of the company’s stock worth $596,000 after buying an additional 76 shares in the last quarter. Great Lakes Advisors LLC increased its stake in shares of Axsome Therapeutics by 1.3% during the fourth quarter. Great Lakes Advisors LLC now owns 6,765 shares of the company’s stock valued at $1,236,000 after buying an additional 89 shares during the period. Smartleaf Asset Management LLC increased its stake in shares of Axsome Therapeutics by 87.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 374 shares of the company’s stock valued at $68,000 after buying an additional 175 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Axsome Therapeutics by 1.2% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,183 shares of the company’s stock valued at $2,316,000 after acquiring an additional 260 shares in the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on AXSM. Leerink Partners boosted their target price on Axsome Therapeutics from $150.00 to $205.00 and gave the company an “outperform” rating in a research report on Wednesday, January 28th. Oppenheimer reaffirmed an “outperform” rating and set a $220.00 price objective on shares of Axsome Therapeutics in a research note on Wednesday, December 31st. TD Cowen reiterated a “buy” rating on shares of Axsome Therapeutics in a research report on Thursday, January 29th. Needham & Company LLC reissued a “buy” rating and issued a $225.00 target price on shares of Axsome Therapeutics in a research note on Monday, January 5th. Finally, HC Wainwright raised their target price on shares of Axsome Therapeutics from $200.00 to $260.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Eighteen analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $210.65.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.